ArticleCurrent drug delivery2026
Mesoporous Silica Nanoparticles with Dual Function of Anti-Inflammatory and Lubrication for Rheumatoid Arthritis Treatment.
Article in Current drug delivery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
introductionRheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease leading to cartilage degeneration and destruction. Friction between articular cartilage surfaces exacerbates these effects. Currently, clinical therapy is dominated by single anti-inflammatory or lubrication treatments. Preparations with both anti-inflammatory and lubrication effects are of great significance for RA treatment. In this study, a mesoporous silica nanosystem (MSN@DCF-HA) with dual functions of anti-inflammation and joint lubrication was developed for RA therapy.
methodsMesoporous silica nanoparticles (MSN) were prepared by the template method. MSN@DCF-HA was synthesized by encapsulating diclofenac (DCF) into MSN and then coating it with hyaluronic acid (HA). Drug loading capacity, encapsulation efficiency, in vitro release, and biosafety of MSN@DCF-HA were evaluated. An RA rat inflammation model was used to assess therapeutic efficacy.
resultsTEM revealed that MSN@DCF-HA was spherical and size-uniform. Experiments demonstrated favorable biocompatibility and stability. The system facilitated sustained DCF release in acidic PBS. In vivo results showed significant reduction in paw swelling, inflammatory factors, and bone damage in the MSN@DCF-HA group. Cell toxicity experiments, hemolysis experiments, and in vivo experiments indicated that it has no significant toxicity. DISCUSSION: MSN@DCF-HA, by loading DCF to exert anti-inflammatory effects and HA to provide external lubrication, joint protection, and synergistic treatment of RA, has demonstrated excellent therapeutic effects, providing a new strategy for RA treatment.
conclusionMSN@DCF-HA was successfully prepared, exhibited slow drug release in acidic environments, and its anti-inflammation and joint lubrication exerted synergistic effects on RA rats without obvious toxicity. This work proposes a novel therapeutic strategy for rheumatoid arthritis.
Indexed as
Identifiers
41572762What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.